

## Authority to prescribe and supply certain restricted substances

I, Bruce Battye, Acting Chief Pharmacist and delegate of the Health Secretary, pursuant to clauses 170 and 171 of the *Poisons and Therapeutic Goods Regulation 2008* (NSW) [Regulation] do hereby:

1. Cancel the authority signed on 8 May 2001 and **attached** to this instrument; and
2. Grant Authority to medical practitioners as a class of persons to prescribe and supply restricted substance listed in the **Schedule** hereunder for the purpose of clauses 37(2) and 52(2) of the Regulation.

### 1. Conditions

- 1) The medical practitioner is employed or engaged in a hospital.
- 2) The medical practitioner is of the opinion that a patient requires the use of the substance in the course of treatment as an inpatient in the hospital.
- 3) The patient was prescribed a course of treatment with the substance by a medical practitioner with authority under Part 8 of the Regulation prior to the patient's admission to the hospital.
- 4) The patient is still undergoing treatment with the substance at the time of their admission to the hospital.

### 2. Validity

This instrument commences on signature and remains in effect until cancelled.

### 3. Definitions

In this instrument:

- *hospital* has the same meaning as in the Regulation.

### Schedule

acitretin  
clomiphene  
cyclofenil  
etretinate  
isotretinoin for oral use



BRUCE BATTYE  
Acting Chief Pharmacist  
(Delegation Numbers PH380, PH381)

Date: 3 MAR 2023

## POISONS AND THERAPEUTIC GOODS ACT 1966

### Authority to Prescribe Certain Restricted Substances

PURSUANT to clauses 147 and 148 of the Poisons and Therapeutic Goods Regulation 1994, I, JOHN LUMBY, Chief Pharmacist, a duly appointed delegate of the Director-General of the Department of Health, do hereby grant **AUTHORITY** to medical practitioners, hereby specified as a class of persons, to prescribe those restricted substances listed in the Schedule hereunder, pursuant to subclause 39 (2) of that Regulation, subject to the following conditions:

- (1) the medical practitioner is an attending medical officer in a public hospital; and
- (2) the medical practitioner is of the opinion that a patient requires the use of the substance in the course of treatment as an in-patient in the public hospital; and
- (3) the patient was prescribed a course of treatment with the substance by a medical practitioner, in accordance with an authority granted to that particular medical practitioner under Part 7 of that Regulation, prior to the patient's admission to that hospital; and
- (4) the patient is still undergoing treatment with the substance at the time of their admission to that hospital.


### SCHEDULE

acitretin  
clomiphene  
cyclofenil  
etretinate  
isotretinoin for oral use

Signed at Sydney this

*eight*

day of May 2001.

  
JOHN LUMBY  
Chief Pharmacist